Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists.

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY Pharmacotherapy Pub Date : 2024-07-01 DOI:10.1002/phar.2922

Elizabeth M Sherman, Allison L Agwu, Juan Ambrosioni, Georg M N Behrens, Carolyn Chu, Lauren F Collins, Humberto R Jimenez, David E Koren, Leslie McGorman, Nancy N Nguyen, Melanie R Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K Scarsi, Gary F Spinner, Alice Tseng, Jeremy D Young, Melissa E Badowski

{"title":"Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists.","authors":"Elizabeth M Sherman, Allison L Agwu, Juan Ambrosioni, Georg M N Behrens, Carolyn Chu, Lauren F Collins, Humberto R Jimenez, David E Koren, Leslie McGorman, Nancy N Nguyen, Melanie R Nicol, Neha Sheth Pandit, Natacha Pierre, Kimberly K Scarsi, Gary F Spinner, Alice Tseng, Jeremy D Young, Melissa E Badowski","doi":"10.1002/phar.2922","DOIUrl":null,"url":null,"abstract":"<p><p>Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.2922","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Five long-acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV-1 prevention or treatment-cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA ARVs into routine clinical practice requires significant changes to the current framework of HIV-1 prevention, treatment, and service provision. Given the novelty, complexity, and interdisciplinary requirements needed to safely and optimally utilize LA ARVs, consensus recommendations on the use of LA ARVs will assist clinicians in optimizing use of these agents. The purpose of these recommendations is to provide guidance for the clinical use of LA ARVs for HIV-1 treatment and prevention. In addition, future areas of research are also identified and discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

关于使用长效抗逆转录病毒药物治疗和预防 HIV-1 的共识建议：经美国艾滋病医学学会、美国临床药学院、加拿大艾滋病和病毒性肝炎药剂师网络、欧洲艾滋病临床学会和传染病药剂师学会认可。

目前，世界上有五种长效（LA）抗逆转录病毒药物（ARV）可在少数国家用于预防或治疗 HIV-1--卡博替拉韦（Cabotegravir）、利匹韦林（rilpivirine）、来那卡韦（lenacapavir）、伊巴利珠单抗（ibalizumab）和达匹韦林（dapivirine）。在常规临床实践中使用 LA 抗逆转录病毒药物需要对目前的 HIV-1 预防、治疗和服务提供框架进行重大变革。鉴于 LA 抗逆转录病毒药物的新颖性、复杂性以及安全和最佳使用 LA 抗逆转录病毒药物所需的跨学科要求，有关使用 LA 抗逆转录病毒药物的共识建议将有助于临床医生优化这些药物的使用。这些建议旨在为临床使用 LA 抗逆转录病毒药物治疗和预防 HIV-1 提供指导。此外，还确定并讨论了未来的研究领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacotherapy 医学-药学

CiteScore

7.80

自引率

2.40%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.